Akcea Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 294

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Akcea Therapeutics General Information

Description

Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.

Contact Information

Website
www.akceatx.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 22 Boston Wharf Road
  • 9th Floor
  • Boston, MA 02210
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akcea Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Akcea Therapeutics‘s full profile, request access.

Request a free trial

Akcea Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs t
Biotechnology
Boston, MA
294 As of 2019
00000
00.000 0000-00-00
000000&0 00000

000 00

etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000 0000-00-00
000000000000 00000

000000

eprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exc
0000000000000
Fremont, CA
000 As of 0000
00000
00.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akcea Therapeutics Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA 000 00000 000000000000 00000
CymaBay Therapeutics Formerly VC-backed Fremont, CA 000 00000 000000&0 00000
Intercept Pharmaceuticals Formerly VC-backed Morristown, NJ 000 00000 000000&0 00000
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 000.00 000000000 - 000.00
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 20 competitors. Get the full list »

Akcea Therapeutics Executive Team (17)

Name Title Board Seat Contact Info
Michael Price Executive Vice President & Chief Financial Officer
You’re viewing 1 of 17 executive team members. Get the full list »

Akcea Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akcea Therapeutics Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Akcea Therapeutics‘s full profile, request access.

Request a free trial

Akcea Therapeutics ESG

Risk Overview

Risk Rating

Updated January, 20, 2020

48.4 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 13,707

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 846

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 415

Rank

00.00

Percentile

To view Akcea Therapeutics’s complete esg history, request access »

Akcea Therapeutics FAQs

  • When was Akcea Therapeutics founded?

    Akcea Therapeutics was founded in 2014.

  • Where is Akcea Therapeutics headquartered?

    Akcea Therapeutics is headquartered in Boston, MA.

  • What is the size of Akcea Therapeutics?

    Akcea Therapeutics has 294 total employees.

  • What industry is Akcea Therapeutics in?

    Akcea Therapeutics’s primary industry is Biotechnology.

  • Is Akcea Therapeutics a private or public company?

    Akcea Therapeutics is a Private company.

  • What is the current valuation of Akcea Therapeutics?

    The current valuation of Akcea Therapeutics is 00.000.

  • What is Akcea Therapeutics’s current revenue?

    The current revenue for Akcea Therapeutics is 000000.

  • How much funding has Akcea Therapeutics raised over time?

    Akcea Therapeutics has raised $175M.

  • Who are Akcea Therapeutics’s investors?

    Novartis has invested in Akcea Therapeutics.

  • Who are Akcea Therapeutics’s competitors?

    NGM Biopharmaceuticals, CymaBay Therapeutics, Intercept Pharmaceuticals, Amgen, and Alnylam Pharmaceuticals are some of the 20 competitors of Akcea Therapeutics.

  • When was Akcea Therapeutics acquired?

    Akcea Therapeutics was acquired on 12-Oct-2020.

  • Who acquired Akcea Therapeutics?

    Akcea Therapeutics was acquired by Ionis Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »